Jonathan Keisling November 13, 2019
In recent months, several lawmakers have
released various versions of a Medicare buy-in proposal. Nearly all of them
include allowing people aged 50 to 64 to buy into Medicare. In the following
report, the Center for Health and Economy (H&E) evaluates the impact of one
of these bills – H.R. 1346, “The Medicare Buy-in and Health Care Stabilization
Act of 2019,” referred to in this paper as “the bill” – beginning in the year
2022.[1] Consistent with other variations of
Medicare buy-in, the bill would allow people from 50-64 years old to buy
Medicare coverage for a premium based on the cost of their benefits, and it
includes many individual market reforms.
Using its Under-65 Microsimulation Model,
H&E analyzed the bill’s impact on health insurance coverage, provider
access, medical productivity, and the federal budget. This report details the
results of that analysis. All impacts projected in this report are relative to H&E’s July
2019 Baseline.[2] As with all projections, the estimates
are associated with some degree of uncertainty.
KEY FINDINGS:
·
Premium
Impact: Premiums are expected to
be reduced by 4 to 12 percent in all metal levels with the exception of
single-coverage Gold plans – the category that includes the Medicare buy-in
plans. This reduction is largely due to the bill’s creation of a reinsurance
fund. Notably, the Medicare buy-in plan premiums are expected to grow at a
faster rate than individual market plans with comparable value.
·
Coverage
Impact: These policies are
projected to lead to marginal increases in the size of the insured population
within the individual marketplace. Initially the bill would lead to an increase
in the individual market of roughly 1 million people. By 2029, however, the
increase in individual market coverage will be less than 500,000 relative to
the baseline.
·
Medicare
Buy–In Enrollment:
Nearly 300,000 people are expected to buy into Medicare in its first year. This
number is expected to decrease to less than 200,000 by the year 2029.
·
Medical
Productivity: The bill would lead to a
4 percent decrease in medical productivity by 2029.
·
Provider
Access: The bill would lead to a
9 percent decrease in provider access by 2029.
·
Budget
Impact: The bill is expected to
increase spending by $184 billion between 2020 and 2029. The bill does not
include any offsetting increases in revenue.
ANALYSIS
This analysis uses a microsimulation model
developed for H&E’s use.[3] The model employs micro-data available
through the Medical Expenditure Panel Survey to analyze the effects of health
policies on the health insurance plan choices of the under-65 population and
interpret the resulting impact on national coverage, average insurance
premiums, the federal budget, and the accessibility and efficiency of health
care. The following provisions from the bill and subsequent assumptions are
included in this score.
·
This analysis assumes
that the bill takes effect on January 1, 2020.[4]
·
Those aged 50-64 and not
currently enrolled in another government insurance plan are eligible to
purchase a Medicare buy-in plan.
·
The premiums will be the
average annual per capita amount “for benefits and administrative expenses that
will be payable under parts A, B, and D in the year for all individuals
enrolled,” as per the bill’s language.
o Premiums will be adjusted for geographic
variation and ages.
o For this analysis, the average base premium for
each individual was calculated using benefits and administration expenses
recorded in the 2019 Medicare Trustees Report.[5]
·
People enrolled in the
Medicare buy-in plan are eligible for all premium reduction and cost-sharing
benefits that they would be entitled to under the Affordable Care Act (ACA).
·
This analysis assumes
that the choice for buying into Medicare is similar to the choice of purchasing
a Gold plan with respect to actuarial value.[6]
·
An individual market
reinsurance fund begins in 2020, with two reinsurance thresholds, as detailed
by the bill:
o For 2020-2021, the greater of 80 percent of
costs exceeding $50,000, or $450,000; and
o After 2021, the greater of 80 percent of costs
exceeding $100,000 or $400,000.
·
This analysis assumes
that all individual market insurers participate in the reinsurance program.
·
The bill calls for
increased cost-sharing reductions (CSR) in the individual market. Eligible
individuals at each relevant federal poverty level (FPL) will now be able to
purchase benchmark Silver plans or Medicare buy-in plans at the following
Actuarial Value (AV) levels:
o From 100 percent to 200 percent of FPL: 95
percent AV;
o From 200 percent to 300 percent of FPL: 90
percent AV; and
o From 300 percent to 400 percent of FPL: 85
percent AV.
·
This analysis assumes
that cost-sharing reduction payments to insurers are re-issued beginning in
2020.
Premium Impact
H&E health insurance premium estimates are
based on five plan design categories offered in the individual market:
Platinum, Gold, Silver, Bronze, and catastrophic. Under current law, the
cost-sharing designs of the four metallic categories correspond to approximate
actuarial values: 90 percent, 80 percent, 70 percent, and 60 percent,
respectively. Catastrophic coverage plans refer to two different kinds of
health insurance plans: first, plans that reimburse medical expenses only after
members meet a high deductible – a maximum of $7,900 for an individual under
current law – and second, Short-Term Limited Duration plans. All premium
estimates reflect health insurance prices without any federal subsidies.
Table 1 below presents the average premiums for
the purchased plans in each category between 2020 and 2029.
H&E estimates that the bill will lead to
lower health insurance premiums in every category. Reinsurance is the main
reason that there is expected to be a reduction in premiums, while the
existence of the Medicare buy-in plan and the reintroduction of CSR payments
are expected to contribute as well.
Current law mandates that insurers offer a
Silver plan with reduced cost-sharing for consumers with incomes of 250 percent
of the federal poverty level or lower. In exchange for offering plans with
reduced cost-sharing, insurers were to receive CSR payments to ease the burden
of providing extra benefits. Insurers currently are not receiving these
payments, however, resulting in upward pressure on premiums (especially Silver
premiums). For this analysis, it was assumed that CSR payments were
reintroduced, coinciding with the increase in CSRs in the bill. The
reintroduction of CSR payments to insurers is a significant source of premium
decreases among Silver plans.
H&E estimates that the presence of a
Medicare buy-in option would put downward pressure on premiums due to the types
of consumers that are eligible for a Medicare buy-in: people between the ages
of 50 and 64. Even though the number of people expected to purchase Medicare coverage
are marginal (as seen in Table 5), with the Medicare buy-in attracting these
patients out of the individual market risk pool, the individual market becomes
younger and healthier, leading to reduced premiums.
As can be seen in Table 2, the premiums for the
Medicare buy-in are expected to be higher than comparable plans (Gold) in the
individual market, as shown in Table 1. The bill calculates the Medicare buy-in
premium based upon the average, annual per-capita amount for benefits and
administrative expenses for people enrolled through the buy-in. As this group
is expected to be less healthy, on average, than the rest of the individual
market, the Medicare buy-in premium is expected to be more expensive than
individual market plans with comparable AV.
Reinsurance would provide payments to insurers
that enroll high-cost beneficiaries, thereby offsetting some of the risk that
insurers take on for enrolling such beneficiaries. In this analysis, it is
assumed that insurers would receive payments for the costs they incur for
patients in the 95th percentile of cost – i.e., the most expensive
beneficiaries. Relative to the 2019 baseline projection, H&E expects
reinsurance to put downward pressure on premiums in every metal level. Table 3
below shows the overall changes in premiums due to both CSRs and reinsurance
relative to the baseline.
H&E insurance coverage estimates reflect
health insurance choices for the under-65 population. H&E estimates that
the bill would result in marginal increases in the insured population, with 1
million more consumers obtaining insurance in the year 2029 relative to the
2019 baseline projection. Table 4 below shows the overall projected insurance
levels.
Within the individual marketplace, H&E expects enrollment to increase most outside of the Health Insurance Marketplace created by the ACA, as Table 5 shows below. The bulk of this increase is the result of reduced premiums caused by the healthier risk pool and reinsurance. The bill’s enhanced CSRs are also expected to contribute to the small increases of insured in the Health Insurance Marketplace.
As can be seen in Table 6, roughly 300,000 consumers are expected to purchase insurance through the Medicare buy-in in 2020. This number is expected to decrease to less than 200,000 toward the end of the time considered in this analysis. Because of the cost of the plan relative to similar AV plans in the individual market, very few consumers are expected to purchase Medicare without the help of tax credits and CSRs. Because of the cost, H&E does not expect Medicare buy-in to lead directly to increases in the number of insured people.
In an attempt to evaluate access and
productivity in the health care system, H&E estimates the Medical
Productivity Index (MPI) and the Provider Access Index (PAI). Health insurance
plan designs are associated with varying degrees of access to desired
physicians and facilities, as well as incentives that promote or discourage
efficient use of resources. H&E estimates each index by attributing
productivity (i.e. efficiency) and access scores to the range of plan designs
available and uses the changes in plan choices to project the evolution of
health care quality. These scores for the bill’s impact on the entire health
care system are provided in Tables 7 and 8, below.
H&E expects medical productivity to decrease relative to the 2019 baseline projection as a result of the bill, as Tables 9 below demonstrates. The increased enrollment in Medicare and corresponding decrease in premiums is expected to result in a larger proportion of consumers insured in higher AV plans with lower cost sharing. Lower cost sharing means lower medical productivity (or efficiency), as people are more likely to pursue health care services. By 2029, medical productivity is expected to decrease by 5 percent relative to conditions under current law.
Provider access is also expected to decrease
under the plan. This decline is primarily due to consumers shifting from Gold
plans to Silver. This largely results from the assumption that CSR repayments
would be reissued to insurers. The reinstatement of CSR payments and the
immediate decrease in Silver plan premiums would result in a shift of consumers
from Gold plans to Silver plans. Therefore, though a Medicare buy-in would draw
some consumers into the greater provider access that comes with Medicare, the
shift of consumers from Gold to Silver plans would be greater, resulting in an
overall drop in provider access.
Budgetary Impact
H&E projects that the bill will lead to a
$184 billion net increase in the budget deficit relative to the current H&E
baseline over the next decade. H&E does not assume any new tax; therefore
there is no revenue-raising mechanism in this score. Reinsurance and CSR
payments are both federal payments to insurers, and the combination of the two
payments would result in roughly $194 billion in added spending.
H&E expects, however, a decrease in
individual market insurance subsidies to offset that spending by $10 billion.
Reinsurance, by itself, would likely have a greater impact on premium subsidy
spending. The bill allows premium subsidies to be spent on those purchasing
Medicare coverage, however, offsetting much of the reduction. After spending
increases and decreases interact, the result is a net spending increase.
H&E uses a peer-reviewed microsimulation
model of the health insurance market to analyze various aspects of the health
care system.5 As with all economic forecasting, H&E estimates
are associated with substantial uncertainty. While the estimates provide a good
indication on the nation’s health care outlook, there are a wide range of
possible scenarios that can result from policy changes, and current assumptions
are unlikely to remain accurate over the course of the next 10 years.
Aside from the potential policy changes, the
magnitude of premium changes in the individual market are a specific area of
uncertainty in this report. The introduction of a substantial, federally funded
reinsurance program would reduce risk for insurers in the individual market and
put downward pressure on premiums; it is unclear, however, how much premiums
will change – especially in the earlier years of the budget window considered.
It is possible that insurers would be more cautious in setting premiums in the
earlier years of such a program.
H&E also assumed no effect on negotiated
rates between insurers and providers as a result of moving roughly 200,000
individuals from the individual marketplace into Medicare. Presumably such
action would place upward pressure on premiums in the individual market as
hundreds of thousands of people become covered at Medicare rates rather than
private rates.
Next, the bill authorizes the Secretary of
Health and Human Services to charge a fee from insurers that wish to
participate in the reinsurance program. The bill does not stipulate, however,
how the Secretary should implement it, the amount of the fee, or whether the
Secretary must charge this fee in order to establish a reinsurance program. Due
to this ambiguity, this analysis does not include this portion charged to
insurers.
There are many implications of this assumption.
Any fee that would be charged to insurers for the establishment of such a
program would likely result in increased premiums. Increased premiums would
then lead to lower individual market enrollment, or higher federal spending on
subsidies, or both.
Another substantial source of uncertainty stems
from implementation of the bill’s increased CSRs. In 2017, CSR payments to
insurers were discontinued. While these payments are still included in current
law, they are not appropriated. The bill does not specify whether CSR payments
to insurers will recontinue. For this analysis, it was assumed that CSR
payments to insurers would recommence for the sake of consistency. If the bill
were passed yet insurers were not reimbursed for CSR payments, premium levels,
enrollment, and costs to the federal government would all be impacted.
[3]
More information on the H&E Under-65 Microsimulation Model can be found at
http://healthandeconomy.org/models/under-65-microsimulation/
[4]
H.R. 1346 begins implementation in the year 2019. For this analysis, it is
assumed that implementation begins in 2020. That is the only assumption that
contradictory to the timeline stipulated by the bill.
[5]
https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ReportsTrustFunds/Downloads/TR2019.pdf
https://www.americanactionforum.org/research/the_medicare_buy-in_and_health_care_stabilization_act_of_2019/#ixzz65HqTNawh
Follow @AAF on Twitter
Follow @AAF on Twitter
No comments:
Post a Comment